Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis

This publication has 7 references indexed in Scilit:

• Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial
  The Lancet Rheumatology, 2024
• Simultaneous Assessment of mTORC1, JAK/STAT, and NLRP3 Inflammasome Activation Pathways in Patients with Sarcoidosis
  International Journal of Molecular Sciences, 2023
• Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
  Nature Communications, 2022
• ERS clinical practice guidelines on treatment of sarcoidosis
  European Respiratory Journal, 2021
• The Role of the Adipokine Leptin in Immune Cell Function in Health and Disease
  Frontiers in Immunology, 2021
• Successful Response to Treatment with Sirolimus in Pulmonary Sarcoidosis
  American Journal of Respiratory and Critical Care Medicine, 2020
• Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia
  European Respiratory Journal, 2018